Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL29706371 | 0.89 | — | — | |
| Acetic Acid SCHEMBL7472549 | 0.84 | — | — | |
| Acetic Acid SCHEMBL1331810 | 0.84 | — | — | |
| Acetic Acid SCHEMBL1330415 | 0.84 | — | — | |
| Acetic Acid SCHEMBL41073 | 0.84 | FFAR3 (1.00) | — | |
| Acetic Acid SCHEMBL1674512 | 0.84 | FFAR3 (1.00) | — | |
| Acetic Acid SCHEMBL11142541 | 0.84 | FFAR3 (1.00) | — | |
| Acetic Acid SCHEMBL8742314 | 0.84 | FFAR3 (1.00) | — | |
| Acetic Acid SCHEMBL1331719 | 0.84 | — | — | |
| Acetic Acid SCHEMBL6788 | 0.84 | FFAR3 (1.00) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8710032-B2 | Inhibitors of the mevalonate pathway of Streptococcus pneumoniae | NORTHWESTERN UNIVERSITY (US) | 2014-04-29 | — | — | US | disclosed |
| US-8673552-B2 | Druggable regions in the dengue virus envelope glycoprotein and methods of using the same | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2014-03-18 | — | — | US | disclosed |
| US-20110178043-A1 | Inhibitors of the mevalonate pathway of streptococcus pneumoniae | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-07-21 | — | — | US | disclosed |
| US-20100298164-A1 | STRUCTURE-BASED APPROACH TO DESIGN OF INHIBITORS OF PROTEIN-PROCESSIVITY FACTOR INTERACTIONS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2010-11-25 | — | — | US | disclosed |
| US-7799547-B2 | Purified polypeptides from Staphylococcus aureus | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2010-09-21 | — | — | US | disclosed |
| US-20100105151-A1 | Novel Druggable Regions in the Dengue Virus Envelope Glycoprotein and Methods of Using the Same | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2010-04-29 | — | — | US | disclosed |
| US-7601526-B2 | Purified FabI polypeptides from Fransicella tularensis | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2009-10-13 | — | — | US | disclosed |
| US-20090132178-A1 | Crystalline enoyl-(acyl-carrier-protein) Reductase from Heliobacter Pylori | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2009-05-21 | — | — | US | disclosed |
| US-7524624-B2 | Druggable regions in the dengue virus envelope glycoprotein and methods of using the same | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2009-04-28 | — | — | US | disclosed |
| US-20090035753-A9 | Novel druggable regions in the dengue virus envelope glycoprotein and methods of using the same | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-02-05 | — | — | US | disclosed |
| EP-0862621-A1 | CRYSTALLINE FRAP COMPLEX | CORNELL RESEARCH FOUNDATION, INC. (US) | 1998-09-09 | — | — | EP | disclosed |
| EP-0847443-A1 | CRYSTALLINE ZAP FAMILY PROTEINS | ARIAD PHARMACEUTICALS, INC. (US) | 1998-06-17 | — | — | EP | disclosed |
| WO-1997008300-A9 | CRYSTALLINE ZAP FAMILY PROTEINS | — | 1997-05-22 | — | — | WO | disclosed |
| WO-1997015659-A1 | CRYSTALLINE FRAP COMPLEX | CORNELL RESEARCH FOUNDATION, INC. (US) | 1997-05-01 | — | — | WO | disclosed |
| WO-1997008300-A1 | CRYSTALLINE ZAP FAMILY PROTEINS | ARIAD PHARMACEUTICALS, INC. (US) | 1997-03-06 | — | — | WO | disclosed |
| EP-0646599-A2 | Modification of pertussis toxin | CONNAUGHT LABORATORIES LIMITED (CA) | 1995-04-05 | — | — | EP | disclosed |
| US-4554397-A | Use of a catalyst comprising nickel and at least one metal from the group consisting of tin, germanium and lead | INSTITUT FRANCAIS DU PETROLE (FR) | 1985-11-19 | — | — | US | disclosed |
| US-4247689-A | Preparation of isocyanate derivatives of 1,3[oxazoles, oxazines, diazoles and diazines] | BAYER AKTIENGESELLSCHAFT (DE) | 1981-01-27 | — | — | US | disclosed |
| US-4242489-A | Process for preparing polyurethanes | BAYER AKTIENGESELLSCHAFT (DE) | 1980-12-30 | — | — | US | disclosed |
| US-4173567-A | Isocyanate derivatives of 1,3[oxazoles, oxazines, diazoles and diazines] | BAYER AKTIENGESELLSCHAFT (DE) | 1979-11-06 | — | — | US | disclosed |